Literature DB >> 32182346

Evaluation of five carbapenemase detection assays for Enterobacteriaceae harbouring blaKPC variants associated with ceftazidime/avibactam resistance.

Paolo Gaibani1, Donatella Lombardo1, Claudio Foschi1,2, Maria Carla Re1,2, Simone Ambretti1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32182346     DOI: 10.1093/jac/dkaa079

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


× No keyword cloud information.
  4 in total

Review 1.  Resistance to Ceftazidime/Avibactam, Meropenem/Vaborbactam and Imipenem/Relebactam in Gram-Negative MDR Bacilli: Molecular Mechanisms and Susceptibility Testing.

Authors:  Paolo Gaibani; Tommaso Giani; Federica Bovo; Donatella Lombardo; Stefano Amadesi; Tiziana Lazzarotto; Marco Coppi; Gian Maria Rossolini; Simone Ambretti
Journal:  Antibiotics (Basel)       Date:  2022-05-06

2.  Implementation of Chromatic Super CAZ/AVI® medium for active surveillance of ceftazidime-avibactam resistance: preventing the loop from becoming a spiral.

Authors:  Gabriele Bianco; Matteo Boattini; Sara Comini; Alessio Leone; Alessandro Bondi; Teresa Zaccaria; Rossana Cavallo; Cristina Costa
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2022-08-06       Impact factor: 5.103

3.  Meropenem-Vaborbactam as Salvage Therapy for Ceftazidime-Avibactam-, Cefiderocol-Resistant ST-512 Klebsiella pneumoniae-Producing KPC-31, a D179Y Variant of KPC-3.

Authors:  Giusy Tiseo; Marco Falcone; Alessandro Leonildi; Cesira Giordano; Simona Barnini; Gabriele Arcari; Alessandra Carattoli; Francesco Menichetti
Journal:  Open Forum Infect Dis       Date:  2021-03-20       Impact factor: 3.835

Review 4.  Treatment options for K. pneumoniae, P. aeruginosa and A. baumannii co-resistant to carbapenems, aminoglycosides, polymyxins and tigecycline: an approach based on the mechanisms of resistance to carbapenems.

Authors:  Stamatis Karakonstantis; Evangelos I Kritsotakis; Achilleas Gikas
Journal:  Infection       Date:  2020-09-01       Impact factor: 3.553

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.